Form 4: Ingevity Director J. Kevin Willis Receives Stock Grant

Director J. Kevin Willis acquired 1,904 deferred stock units in lieu of an annual restricted stock unit grant.

Summary

• Director J. Kevin Willis was granted 1,904 deferred stock units (DSUs) on April 30, 2026.
• The grant was made in lieu of the standard annual non-employee director restricted stock unit grant.
• Following this transaction, the director's total beneficial ownership of Ingevity common stock is 11,081 shares.
• The DSUs are scheduled to vest on April 30, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• The transaction reflects an alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• The value of the deferred stock units is subject to the future market performance of Ingevity common stock.

Future Outlook

The DSUs will settle into an equal number of shares of common stock upon the director's termination of board service, subject to the company's deferred compensation and incentive plans.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation, common among publicly traded companies to ensure transparency in board-level equity holdings.

Comparison to Industry Standards

• The use of deferred stock units in lieu of restricted stock is a standard corporate governance practice for aligning director compensation with long-term company performance.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• Vesting of the 1,904 deferred stock units on April 30, 2027.

Key Dates

Keywords

Ingevity, NGVT, Form 4, Director Compensation, Insider Trading, Equity Grant